Top Democrats on the House Energy and Commerce Committee have formally requested information from the Centers for Disease Control and Prevention (CDC) regarding a controversial hepatitis B clinical trial currently underway in Guinea-Bissau. The inquiry follows the CDC’s decision last year to award $1.6 million in funding to a team of Danish researchers to conduct the study in the West African nation.

While the specific nature of the controversy remains largely unaddressed in initial reporting, the committee’s request signals a push for greater transparency and oversight regarding how federal health funds are utilized in international research projects. The lawmakers are seeking clarification on the study's design, ethical considerations, and the CDC's role in monitoring the project. As of now, the CDC has not issued a detailed public response to the committee's demands, and the specific concerns driving the lawmakers' request have not been fully disclosed to the public. The situation highlights ongoing legislative interest in the accountability of federal agencies when they partner with foreign entities for medical research.